MedTrace Logo

REMdesivir-HU Clinical Study and Severe Covid-19 Patients

NCT04610541 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2020-11-27

No results posted yet for this study

Summary

This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.

Conditions

Interventions

DRUG

Remdesivir-HU

Remdesivir-HU 100 mg concentrate for solution for infusion

Sponsors & Collaborators

  • HECRIN Consortium

    collaborator UNKNOWN

  • Hungarian Ministry of Innovation and Technology

    collaborator UNKNOWN

  • University of Pecs

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-12
Primary Completion
2021-10-30
Completion
2021-11-30

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04610541 on ClinicalTrials.gov